127 related articles for article (PubMed ID: 37699709)
1. First-in-Human Phase 1 Randomized Trial with the Anti-CD40 Monoclonal Antibody KPL-404: Safety, Tolerability, Receptor Occupancy, and Suppression of T-Cell-Dependent Antibody Response.
Samant M; Ziemniak J; Paolini JF
J Pharmacol Exp Ther; 2023 Dec; 387(3):306-314. PubMed ID: 37699709
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Immunopharmacologic Assessment of KPL-404, a Novel, Humanized, Non-Depleting Antagonistic Anti-CD40 Monoclonal Antibody.
Muralidharan S; Njenga M; Garron T; Bondensgaard K; Paolini JF
J Pharmacol Exp Ther; 2022 Apr; 381(1):12-21. PubMed ID: 35078863
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
[TBL] [Abstract][Full Text] [Related]
4. First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody.
Espié P; He Y; Koo P; Sickert D; Dupuy C; Chokoté E; Schuler R; Mergentaler H; Ristov J; Milojevic J; Verles A; Groenewegen A; Auger A; Avrameas A; Rotte M; Colin L; Tomek CS; Hernandez-Illas M; Rush JS; Gergely P
Am J Transplant; 2020 Feb; 20(2):463-473. PubMed ID: 31647605
[TBL] [Abstract][Full Text] [Related]
5. Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases.
Schwabe C; Rosenstock B; Doan T; Hamilton P; Dunbar PR; Eleftheraki AG; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
J Clin Pharmacol; 2018 Dec; 58(12):1566-1577. PubMed ID: 30113724
[TBL] [Abstract][Full Text] [Related]
6. A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation.
Vincenti F; Klintmalm G; Yang H; Ram Peddi V; Blahunka P; Conkle A; Santos V; Holman J
Am J Transplant; 2020 Jan; 20(1):172-180. PubMed ID: 31397943
[TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients.
Marken J; Muralidharan S; Giltiay NV
Arthritis Res Ther; 2021 Jan; 23(1):5. PubMed ID: 33407802
[TBL] [Abstract][Full Text] [Related]
9. A Phase 1 Single-Ascending-Dose Trial in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous PNT001, a Novel Mid-domain Tau Antibody Targeting cis-pT231 Tau.
Luca W; Foster K; McClure K; Ahlijanian MK; Jefson M
J Prev Alzheimers Dis; 2024; 11(2):366-374. PubMed ID: 38374743
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.
Johnson ML; Braiteh F; Grilley-Olson JE; Chou J; Davda J; Forgie A; Li R; Jacobs I; Kazazi F; Hu-Lieskovan S
JAMA Oncol; 2019 Jul; 5(7):999-1007. PubMed ID: 31145415
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials.
Choy EH; Bendit M; McAleer D; Liu F; Feeney M; Brett S; Zamuner S; Campanile A; Toso J
Arthritis Res Ther; 2013 Sep; 15(5):R132. PubMed ID: 24286335
[TBL] [Abstract][Full Text] [Related]
12. Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.
Hua F; Comer GM; Stockert L; Jin B; Nowak J; Pleasic-Williams S; Wunderlich D; Cheng J; Beebe JS
J Clin Pharmacol; 2014 Jan; 54(1):14-22. PubMed ID: 23913720
[TBL] [Abstract][Full Text] [Related]
13. Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study.
Ellis J; van Maurik A; Fortunato L; Gisbert S; Chen K; Schwartz A; McHugh S; Want A; Santos Franco S; Oliveira JJ; Price J; Coles A; Brown K; Su D; Craigen JL; Yang J; Brett S; Davis B; Cheriyan J; Kousin-Ezewu O; Gray F; Thompson PW; Fernando D
Br J Clin Pharmacol; 2019 Feb; 85(2):304-315. PubMed ID: 30161291
[TBL] [Abstract][Full Text] [Related]
14. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.
White B; Leon F; White W; Robbie G
Clin Ther; 2009 Apr; 31(4):728-40. PubMed ID: 19446146
[TBL] [Abstract][Full Text] [Related]
15. A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers.
Kostic A; King TA; Yang F; Chan KC; Yancopoulos GD; Gromada J; Harp JB
Diabetes Obes Metab; 2018 Feb; 20(2):283-291. PubMed ID: 28755409
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study.
Tabuchi H; Katsurabara T; Mori M; Aoyama M; Obara T; Yasuda N; Kawano T; Imai T; Ieiri I; Kumagai Y
J Clin Pharmacol; 2019 May; 59(5):688-701. PubMed ID: 30575978
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects.
Shi R; Honczarenko M; Zhang S; Fleener C; Mora J; Lee SK; Wang R; Liu X; Shevell DE; Yang Z; Wang H; Murthy B
J Clin Pharmacol; 2017 Feb; 57(2):161-172. PubMed ID: 27402064
[TBL] [Abstract][Full Text] [Related]
18. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
Cardinal M; Kantaridis C; Zhu T; Sun P; Pittman DD; Murphy JE; Arkin S
J Thromb Haemost; 2018 Sep; 16(9):1722-1731. PubMed ID: 29908043
[TBL] [Abstract][Full Text] [Related]
19. A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects.
Hussaini A; Mukherjee R; Berdieva DM; Glogowski C; Mountfield R; Ho PTC
Clin Transl Sci; 2020 Mar; 13(2):337-344. PubMed ID: 31664766
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects.
Li Z; Radin A; Li M; Hamilton JD; Kajiwara M; Davis JD; Takahashi Y; Hasegawa S; Ming JE; DiCioccio AT; Li Y; Kovalenko P; Lu Q; Ortemann-Renon C; Ardeleanu M; Swanson BN
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):742-755. PubMed ID: 32348036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
